Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2020.607918 http://scihub22266oqcxt.onion/10.3389/fimmu.2020.607918 33424856!7785785!33424856     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2020 ; 11 (ä): 607918 Nephropedia Template TP {{tp|p=33424856|t=2020. HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients |pdf=|usr=}}{{33424856}} gab.com Text HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33424856 #FOAvip The inability of patients with CVID to mount specific antibody responses to pathogens has raised concerns on the risk and severity of SARS-CoV-2 infection, but there might be a role for protective T cells in these patients. SARS-CoV-2 reactive T cells have been reported for SARS-CoV-2 unexposed healthy individuals. Until now, there is no data on T cell immunity to SARS-CoV-2 infection in CVID. This study aimed to evaluate reactive T cells to human endemic corona viruses (HCoV) and to study pre-existing SARS-CoV-2 reactive T cells in unexposed CVID patients. We evaluated SARS-CoV-2- and HCoV-229E and -OC43 reactive T cells in response to seven peptide pools, including spike and nucleocapsid (NCAP) proteins, in 11 unexposed CVID, 12 unexposed and 11 post COVID-19 healthy controls (HC). We further characterized reactive T cells by IFNgamma, TNFalpha and IL-2 profiles. SARS-CoV-2 spike-reactive CD4+ T cells were detected in 7 of 11 unexposed CVID patients, albeit with fewer multifunctional (IFNgamma/TNFalpha/IL-2) cells than unexposed HC. CVID patients had no SARS-CoV-2 NCAP reactive CD4+ T cells and less reactive CD8+ cells compared to unexposed HC. We observed a correlation between T cell reactivity against spike of SARS-CoV-2 and HCoVs in unexposed, but not post COVID-19 HC, suggesting cross-reactivity. T cell responses in post COVID-19 HC could be distinguished from unexposed HC by higher frequencies of triple-positive NCAP reactive CD4+ T cells. Taken together, SARS-CoV-2 reactive T cells are detectable in unexposed CVID patients albeit with lower recognition frequencies and polyfunctional potential. Frequencies of triple-functional reactive CD4+ cells might provide a marker to distinguish HCoV cross-reactive from SARS-CoV-2 specific T cell responses. Our data provides evidence, that anti-viral T cell immunity is not relevantly impaired in most CVID patients. Twit Text FOAVip HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33424856 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33424856 #FOAvip English Wikipedia <ref>{{Cite pmid|33424856}}</ref> HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients #MMPMID33424856 Steiner S; Sotzny F; Bauer S; Na IK; Schmueck-Henneresse M; Corman VM; Schwarz T; Drosten C; Wendering DJ; Behrends U; Volk HD; Scheibenbogen C; Hanitsch LG Front Immunol 2020[]; 11 (ä): 607918 PMID33424856show ga The inability of patients with CVID to mount specific antibody responses to pathogens has raised concerns on the risk and severity of SARS-CoV-2 infection, but there might be a role for protective T cells in these patients. SARS-CoV-2 reactive T cells have been reported for SARS-CoV-2 unexposed healthy individuals. Until now, there is no data on T cell immunity to SARS-CoV-2 infection in CVID. This study aimed to evaluate reactive T cells to human endemic corona viruses (HCoV) and to study pre-existing SARS-CoV-2 reactive T cells in unexposed CVID patients. We evaluated SARS-CoV-2- and HCoV-229E and -OC43 reactive T cells in response to seven peptide pools, including spike and nucleocapsid (NCAP) proteins, in 11 unexposed CVID, 12 unexposed and 11 post COVID-19 healthy controls (HC). We further characterized reactive T cells by IFNgamma, TNFalpha and IL-2 profiles. SARS-CoV-2 spike-reactive CD4+ T cells were detected in 7 of 11 unexposed CVID patients, albeit with fewer multifunctional (IFNgamma/TNFalpha/IL-2) cells than unexposed HC. CVID patients had no SARS-CoV-2 NCAP reactive CD4+ T cells and less reactive CD8+ cells compared to unexposed HC. We observed a correlation between T cell reactivity against spike of SARS-CoV-2 and HCoVs in unexposed, but not post COVID-19 HC, suggesting cross-reactivity. T cell responses in post COVID-19 HC could be distinguished from unexposed HC by higher frequencies of triple-positive NCAP reactive CD4+ T cells. Taken together, SARS-CoV-2 reactive T cells are detectable in unexposed CVID patients albeit with lower recognition frequencies and polyfunctional potential. Frequencies of triple-functional reactive CD4+ cells might provide a marker to distinguish HCoV cross-reactive from SARS-CoV-2 specific T cell responses. Our data provides evidence, that anti-viral T cell immunity is not relevantly impaired in most CVID patients. |Adult[MESH] |Aged[MESH] |Antibodies, Viral/*blood[MESH] |Common Variable Immunodeficiency/blood/*immunology[MESH] |Coronaviridae/*immunology[MESH] |Cross Reactions[MESH] |Cytokines/immunology[MESH] |Female[MESH] |Humans[MESH] |Immunoglobulin G/*blood[MESH] |Male[MESH] |Middle Aged[MESH] |T-Lymphocytes/*immunology[MESH]HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients (epmc).pdf DeepDyve Pubget Overpricing